Proteomic analysis of human plasma in chronic rheumatic mitral stenosis reveals proteins involved in the complement and coagulation cascade

Clinical Proteomics

Volumn 11, Issue 1, 2014, Pages

  Mukherjee, Somaditya ^a   Jagadeeshaprasad, Mashanipalya G ^b   Banerjee, Tanima ^a   Ghosh, Sudip K ^c   Biswas, Monodeep ^d   Dutta, Santanu ^e   Kulkarni, Mahesh J ^b   Pattari, Sanjib ^f   Bandyopadhyay, Arun ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b NATIONAL CHEMICAL LABORATORY   (India)

^c MEDICAL COLLEGE AND HOSPITAL   (India)

^d Department of Cardiology Geisinger Community Medical Center Wright Center for Graduate Medical Education ^*  (United States)

^e INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^f Narayana Health   (India)

Author keywords

Immunotechniques; Inflammation; Mitral Stenosis; Plasma proteomics; Rheumatic fever

Indexed keywords

ALBUMIN; ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN C3; CERULOPLASMIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C4B BINDING PROTEIN; COMPLEMENT FACTOR H; FETUIN A; FIBRINOGEN; FIBRINOGEN ALPHA CHAIN; FIBRINOGEN BETA CHAIN; FIBRINOGEN GAMMAA CHAIN; HAPTOGLOBIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; OROSOMUCOID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; COMPLEMENT SYSTEM; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MIDDLE AGED; MITRAL VALVE STENOSIS; MOLECULAR PATHOLOGY; NUCLEOTIDE SEQUENCE; PREDICTIVE VALUE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEOMICS; RHEUMATIC HEART DISEASE; YOUNG ADULT;

EID: 84910598944     PISSN: 15426416     EISSN: 15590275     Source Type: Journal    
DOI: 10.1186/1559-0275-11-35     Document Type: Article

References (63)

1. Carapetis JR, Steer AC, Mulholland EK, Weber M: The global burden of group A streptococcal diseases. Lancet Infect Dis 2005, 5:685-694. 10.1016/S1473-3099(05)70267-X
2. World Health Organization: Projections of Mortality and Burden of Disease, 2004-2030; Standard DALYs (3% Discounting, Age Weights) -Baseline Scenario. WHO regions; 2011. http://www.who.int/entity/healthinfo/global-burden-disease/DALY7-2008.xls
3. Kadir IS, Barker TA, Clarke B, Denley H, Grötte GJ: Recurrent acute rheumatic fever: a forgotten diagnosis? Ann Thorac Surg 2004, 78:699-701. 10.1016/S0003-4975(03)01376-6
4. Carabello BA: Modern management of mitral stenosis. Circulation 2005, 112:432-437. 10.1161/CIRCULATIONAHA.104.532498
5. Maganti K, Rigolin VH, Sarano ME, Bonow RO: Valvular heart disease: diagnosis and management. Mayo Clin Proc 2010, 85:483-500. 10.4065/mcp.2009.0706
6. Veenstra TD, Conrads TP, Hood BL, Avellino AM, Ellenbogen RG, Morrison RS: Biomarkers: mining the biofluid proteome. Mol Cell Proteomics 2005, 4:409-418. 10.1074/mcp.M500006-MCP200
7. Anderson NL, Anderson NG: The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002, 11:845-867.
8. Zolotarjova N, Martosella J, Nicol G, Bailey J, Boyes BE, Barrett WC: Differences among techniques for high abundant protein depletion. Proteomics 2005, 5:3304-3313. 10.1002/pmic.200402021
9. Wang YY, Cheng P, Chan DW: A simple affinity spin tube filter method for removing high-abundant common proteins or enriching low-abundant biomarkers for serum proteomic analysis. Proteomics 2003, 3:243-248. 10.1002/pmic.200390036
10. Bjorhall K, Miliotis T, Davidsson P: Interest of major serum protein removal for surface-enhanced laser desorption/ionization - time of flight (SELDI-TOF) proteomic blood profiling. Proteomics 2005, 5:307-317. 10.1002/pmic.200400900
11. Seam N, Gonzales DA, Kern SJ, Hortin GL, Hoehn GT, Suffredini AF: Quality control of serum albumin depletion for proteomic analysis. Clin Chem 2007, 53:1915-1920. 10.1373/clinchem.2007.091736
12. Granger J, Siddiqui J, Copeland S, Remick D: Albumin depletion of human plasma also removes low abundance proteins including the cytokines. Proteomics 2005, 5:4713-4718. 10.1002/pmic.200401331
13. Righetti PG, Boschetti E, Lomas L, Citterio A: Protein equalizer technology: the quest for a "democratic proteome". Proteomics 2006, 6:3980-3992. 10.1002/pmic.200500904
14. Sihlbom C, Kanmert I, von Bahr H, Davidsson P: Evaluation of the combination of bead technology with SELDI-TOF-MS and 2-D DIGE for detection of plasma proteins. J Proteome Res 2008, 7:4191-4198. 10.1021/pr800340c
15. Svendsen CB, Hummelshøj T, Munthe-Fog L, Milman N, Garred P, Laursen IA, Christiansen M, Krogfelt KA: Ficolins and Mannose-binding lectin in Danish patients with sarcoidosis. Respir Med 2008, 102:1237-1242. 10.1016/j.rmed.2008.04.012
16. Cunningham SK, Loughlin T, Culliton M, McKenna TJ: Plasma sex hormone-binding globulin levels decrease during the second decade of life irrespective of pubertal status. J Clin Endocrinol Metab 1984, 58:915-918. 10.1210/jcem-58-5-915
17. Bloem LJ, Manatunga AK, Tewksbury DA, Pratt JH: The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. J Clin Invest 1995, 95:948-953. 10.1172/JCI117803
18. O'Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, Otta CM: Apolipoproteins B, and E accumulate in themorphologically early lesion of "degenerative" valvular aorticstenosis. J Arterioscler Thromb Vasc Biol 1996, 16:523-532. 10.1161/01.ATV.16.4.523
19. Olsson M, Thyberg J, Nilsson J: Presence of oxidized low density lipoprotein in non rheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 1999, 19:1218-1222. 10.1161/01.ATV.19.5.1218
20. Walport MJ: Complement: first of two parts. N Engl J Med 2001, 344:1058-1066. 10.1056/NEJM200104053441406
21. Theroux P, Martel C: Complement activity and pharmacological inhibition in cardiovascular disease. Can J Cardiol 2006,22(Suppl. B):18B-24B.
22. Szilagyi A, Fust G: Diseases associated with the low copynumber of the C4B gene encoding C4, the fourth component of complement. Cytogenet Genome Res 2008, 123:118-130. 10.1159/000184699
23. Stastny J, Fosslien E, Robertson AL Jr: Human aortic intima protein composition during initial stages of atherogenesis. Atherosclerosis 1986, 60:131-139. 10.1016/0021-9150(86)90005-5
24. Talmud PJ, Martin S, Steiner G, Flavell DM, Whitehouse DB, Nagl S, Jackson R, Taskinen MR, Frick MH, Nieminen MS, Kesäniemi YA, Pasternack A, Humphries SE, Syvänne M: Diabetes atherosclerosis intervention study investigators: progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. Arterioscler Thromb Vasc Biol 2003, 23:644-649. 10.1161/01.ATV.0000065196.61663.8D
25. Blumenstein M, McMaster MT, Black MA, Wu S, Prakash R, Cooney J, McCowan LM, Cooper GJ, North RA: A proteomic approach identifies early pregnancy biomarkers for preeclampsia: novel linkages between a predisposition to preeclampsia and cardiovascular disease. Proteomics 2009, 9:2929-2945. 10.1002/pmic.200800625
26. Dimitrow PP, Hlawaty M, Undas A, Sniezek-Maciejewska M, Sobień B, Stepień E, Tracz W: Effect of aortic valve stenosis on haemostasis is independent from vascular atherosclerotic burden. Atherosclerosis 2009, 204:e103-e108. 10.1016/j.atherosclerosis.2008.12.029
27. Hansson K, Stenflo J: Post-translational modifications in proteins involved in blood coagulation. J Thromb Haemostasis 2005, 3:2633-2648. 10.1111/j.1538-7836.2005.01478.x
28. Eisenberg S: High-density Lipoprotein Metabolism. In Lipoprotein in Health and Disease. Edited by: Betterridge DJ, Illingworth DR, Sepherd J. London: Arnold; 1999:71-85.
29. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, Vuletic S, Kassim S, Singh P, Chea H, Knopp RH, Brunzell J, Geary R, Chait A, Zhao XQ, Elkon K, Marcovina S, Ridker P, Oram JF, Heinecke JW: Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of HDL. J Clin Invest 2007, 117:746-756. 10.1172/JCI26206
30. Ansell BJ: The two faces of the 'good' cholesterol. Cleve Clini J Med 2007, 74:697-705. 10.3949/ccjm.74.10.697
31. Ma'ayan A: Insights into the organization of biochemical regulatory networks using graph theory analyses. J Biol Chem 2009, 284:5451-5455. 10.1074/jbc.R800056200
32. Jeong H, Mason SP, Baraba'si AL, Oltvai ZN: Lethality and centrality in protein networks. Nature 2001, 411:41-42. 10.1038/35075138
33. Zotenko E, Mestre J, O'Leary DP, Przytycka TM: Why do hubs in the yeast protein interaction network tend to be essential: reexamining the connection between the network topology and essentiality. PLoS Comput Biol 2008, 4:e1000140. 10.1371/journal.pcbi.1000140
34. Sharan R, Ulitsky I, Shamir R: Network-based prediction of protein function. Mol Systems Biol 2007, 3:88-101.
35. Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G: Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979, 64:1118-1129. 10.1172/JCI109551
36. Daveau M, Davrinche C, Julen N, Hiron M, Arnaud P, Lebreton JP: The synthesis of human α-2-HS glycoprotein is down-regulated by cytokines in hepatoma HepG2 cells. FEBS Lett 1988, 241:191-194. 10.1016/0014-5793(88)81059-7
37. Maréchal C, Schlieper G, Nguyen P, Krüger T, Coche E, Robert A, Floege J, Goffin E, Jadoul M, Devuyst O: Serum fetuin-A levels are associated with vascular calcifications and predict cardiovascular events in renal transplant recipients. Clin J Am Soc Nephrol 2011, 6:974-985. 10.2215/CJN.06150710
38. Ix JH, Chertow GM, Shlipak MG, Brandenburg VM, Ketteler M, Whooley MA: Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the heart and soul study. Circulation 2007, 115:2533-2539. 10.1161/CIRCULATIONAHA.106.682450
39. Cagli K, Basar N, Cagli K, Armutcu F, Aylak F, Yalcinkaya A, Erden G, Kadirogullari E: Association of serum fetuin-A with valvular calcium concentration in rheumatic mitral valve disease. J Heart Valve Dis 2010, 19:636-643.
40. Artl A, Marsche G, Lestavel S, Sattler W, Malle E: Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler Thromb Vasc Biol 2000, 20:763-772. 10.1161/01.ATV.20.3.763
41. Murphy AJ, Hoang A, Aprico A, Sviridov D, Chin-Dusting J: Anti-inflammatory functions of apolipoprotein A-I and high-density lipoprotein are preserved in trimeric apolipoprotein A-I. J Pharmacol Exp Ther 2013, 344:41-49. 10.1124/jpet.112.199257
42. Umemoto T, Han CY, Mitra P, Averill MM, Tang C, Goodspeed L, Omer M, Subramanian S, Wang S, Den Hartigh LJ, Wei H, Kim EJ, Kim J, O'Brien KD, Chait A: Apolipoprotein AI and high-density lipoprotein have anti-inflammatory effects on adipocytes via cholesterol transporters: ATP-binding cassette A-1, ATP-binding cassette G-1, and scavenger receptor B-1. Circ Res 2013, 112:1345-1354. 10.1161/CIRCRESAHA.111.300581
43. McLaughlin L, Zhu G, Mistry M, Ley-Ebert C, Stuart WD, Florio CJ, Groen PA, Witt SA, Kimball TR, Witte DP, Harmony JA, Aronow BJ: Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis. J Clin Invest 2000, 106:1105-1113. 10.1172/JCI9037
44. Schwochau GB, Nath KA, Rosenberg ME: Clusterin protects against oxidative stress in vitro through aggregative and nonaggregative properties. Kidney Int 1998, 53:1647-1653. 10.1046/j.1523-1755.1998.00902.x
45. Viard I, Wehrli P, Jornot L, Bullani R, Vechietti JL, Schifferli JA, Tschopp J, French LE: Clusterin gene expression mediates resistance to apoptotic cell death induced by heat shock and oxidative stress. J Invest Dermatol 1999, 112:290-296. 10.1046/j.1523-1747.1999.00531.x
46. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY: Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 2005, 7:909-915. 10.1038/ncb1291
47. Stuart WD1, Krol B, Jenkins SH, Harmony JA: Structure and stability of apolipoprotein J-containing high-density lipoproteins. Biochemistry 1992, 31:8552-8559. 10.1021/bi00151a024
48. Preissner KT: The role of vitronectin as multifunctional regulator in the hemostatic and immune systems. Blut 1989, 59:419-431. 10.1007/BF00349063
49. Declerck PJ, De Mol M, Alessi MC, Baudner S, Pâques EP, Preissner KT, Müller-Berghaus G, Collen D: Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma: identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988, 263:15454-15461.
50. Preissner KT, Holzhuter S, Justus C, Muller-Berghaus G: Identification of and partial characterization of platelet vitronectin: evidence for complex formation with platelet-derived plasminogen activator inhibitor-1. Blood 1989, 74:1989-1996.
51. Thiagarajan P, Kelly KL: Exposure of binding sites for vitronectin on platelets following stimulation. J Biol Chem 1988, 263:3035-3038.
52. Speidl WS, Kastl SP, Huber K, Wojta J: Complement in atherosclerosis: friend or foe? J Thromb Haemost 2011, 9:428-440. 10.1111/j.1538-7836.2010.04172.x
53. Gao G, Xuan C, Yang Q, Liu XC, Liu ZG, He GW: Identification of altered plasma proteins by proteomic study in valvular heart diseases and the potential clinical significance. PloS One 2013, 8:e72111. 10.1371/journal.pone.0072111
54. Bouchey D, Argraves WS, Little CD: Fibulin-1, vitronectin, and fibronectin expression during avian cardiac valve and septa development. Anat Rec 1996, 244:540-551. 10.1002/(SICI)1097-0185(199604)244:4<540::AID-AR12>3.0.CO;2-P
55. Reményi B, Wilson N, Steer A, Ferreira B, Kado J, Kumar K, Lawrenson J, Maguire G, Marijon E, Mirabel M, Mocumbi AO, Mota C, Paar J, Saxena A, Scheel J, Stirling J, Viali S, Balekundri VI, Wheaton G, Zühlke L, Carapetis J: World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease - an evidence-based guideline. Nat Rev Cardiol 2012, 9:297-309. 10.1038/nrcardio.2012.7
56. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
57. E : a virtue of parallel MS acquisition. Mol Cell Proteomics 2006, 5:144-156.
58. Bhonsle HS, Korwar AM, Kote SS, Golegaonkar SB, Chougale AD, Shaik ML, Dhande NL, Giri AP, Shelgikar KM, Boppana R, Kulkarni MJ: Low plasma albumin levels are associated with increased plasma protein glycation and HbA1c in diabetes. J Proteome Res 2012, 11:1391-1396. 10.1021/pr201030m
59. Gil-Dones F, Darde VM, Alonso-Orgaz S, Lopez-Almodovar LF, Mourino-Alvarez L, Padial LR, Vivanco F, Barderas MG: Inside human aortic stenosis: a proteomic analysis of plasma. J Proteomics 2012, 75:1639-1653. 10.1016/j.jprot.2011.11.036
60. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA: DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol 2003, 4:P3. 10.1186/gb-2003-4-5-p3
61. Kanehisa M, Goto S: KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000, 28:27-30. 10.1093/nar/28.1.27
62. Ghose Roy S, Mishra S, Ghosh G, Bandyopadhyay A: Thyroid hormone induces myocardial matrix degradation by activating matrix metalloproteinase-1. Matrix Biol 2007, 26:269-279. 10.1016/j.matbio.2006.12.005
63. Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J, Doerks T, Julien P, Roth A, Simonovic M, Bork P, von Mering C: STRING 8-a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res 2009, 37:D412. 10.1093/nar/gkn760